GB9405856D0 - Pharmaceutical formulation - Google Patents
Pharmaceutical formulationInfo
- Publication number
- GB9405856D0 GB9405856D0 GB9405856A GB9405856A GB9405856D0 GB 9405856 D0 GB9405856 D0 GB 9405856D0 GB 9405856 A GB9405856 A GB 9405856A GB 9405856 A GB9405856 A GB 9405856A GB 9405856 D0 GB9405856 D0 GB 9405856D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- pharmaceutical formulation
- formulation
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9405856A GB9405856D0 (en) | 1994-03-24 | 1994-03-24 | Pharmaceutical formulation |
PCT/EP1995/001039 WO1995025516A1 (en) | 1994-03-24 | 1995-03-20 | Pharmaceutical formulations containing beta-lactam antibiotics and an alkyl sulphate surfactant |
JP7524382A JPH09510470A (en) | 1994-03-24 | 1995-03-20 | Pharmaceutical formulations containing beta-lactam antibiotics and alkyl sulphate surfactants |
EP95928859A EP0751771A1 (en) | 1994-03-24 | 1995-03-20 | Pharmaceutical formulations containing beta-lactam antibiotics and an alkyl sulphate surfactant |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9405856A GB9405856D0 (en) | 1994-03-24 | 1994-03-24 | Pharmaceutical formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
GB9405856D0 true GB9405856D0 (en) | 1994-05-11 |
Family
ID=10752439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB9405856A Pending GB9405856D0 (en) | 1994-03-24 | 1994-03-24 | Pharmaceutical formulation |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0751771A1 (en) |
JP (1) | JPH09510470A (en) |
GB (1) | GB9405856D0 (en) |
WO (1) | WO1995025516A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR004510A1 (en) | 1995-09-07 | 1998-12-16 | Smithkline Beecham Plc | COMPOSITIONS INCLUDING AMOXICILLIN AND CLAVULANATE, PROCEDURES FOR ITS PREPARATION AND THE USE OF COMPOSITIONS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
DE69815833T2 (en) * | 1997-02-14 | 2004-05-19 | Laboratoire Glaxosmithkline S.A.S. | MEDICAL PREPARATIONS CONTAINING AMOXICILLIN AND CLAVULANATE |
SE9700885D0 (en) * | 1997-03-12 | 1997-03-12 | Astra Ab | New pharmaceutical formulation |
US6878386B1 (en) | 1999-04-13 | 2005-04-12 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate |
US7250176B1 (en) | 1999-04-13 | 2007-07-31 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection |
US6294199B1 (en) * | 1999-04-13 | 2001-09-25 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising administering amoxycillin |
GB9930578D0 (en) * | 1999-12-23 | 2000-02-16 | Smithkline Beecham Plc | Pharmaceutical formulations |
WO2002030392A2 (en) | 2000-10-12 | 2002-04-18 | Beecham Pharmaceuticals (Pte) Limited | Formulation containing amoxicillin |
US6756057B2 (en) | 2000-10-12 | 2004-06-29 | Beecham Pharmaceuticals (Pte) Limited | Amoxicillin and potassium clavulanate dosage form |
AU2002315287A1 (en) * | 2001-04-12 | 2002-10-28 | Sandoz Gmbh | Pharmaceutical composition comprising clavulanic acid |
AT413983B (en) * | 2001-04-12 | 2006-08-15 | Sandoz Ag | Pharmaceutical composition useful for reducing rapid degradation of the active ingredient comprises clavulanate, in the form of granulated and hydrophobised particles, and an active ingredient |
AT412344B (en) * | 2001-04-12 | 2005-01-25 | Sandoz Ag | Pharmaceutical composition useful for reducing rapid degradation of the active ingredient comprises clavulanate, in the form of granulated and hydrophobised particles, and an active ingredient |
CA2459014C (en) * | 2001-09-14 | 2010-08-10 | Scolr, Inc. | Amino acid modulated extended release dosage form |
WO2006072577A1 (en) * | 2005-01-07 | 2006-07-13 | Sandoz Ag | Process for preparing granulates comprising amoxicillin |
AU2008317315A1 (en) * | 2007-10-26 | 2009-04-30 | Rexahn Pharmaceuticals, Inc. | Pharmaceutical formulation of clavulanic acid |
CN112587481B (en) * | 2020-12-28 | 2022-03-15 | 成都中牧生物药业有限公司 | Alkalescent amoxicillin soluble powder and preparation method thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2523446A1 (en) * | 1982-03-19 | 1983-09-23 | Dietlin Francois | Controlled release pharmaceutical compsns. - for oral admin. contg. konjak mannan(s) and surfactant |
GB8400024D0 (en) * | 1984-01-03 | 1984-02-08 | Glaxo Group Ltd | Cephalosporin antibiotics |
WO1988009173A1 (en) * | 1987-05-27 | 1988-12-01 | Akzo N.V. | DRY, RAPIDLY SOLUBLE, COMPOSITIONS OF beta-LACTAM ANTIBIOTICS |
NZ234587A (en) * | 1989-08-04 | 1991-11-26 | Mcneil Ppc Inc | A chewable pharmaceutical tablet of compressed coated granules |
GB9009473D0 (en) * | 1990-04-27 | 1990-06-20 | Beecham Group Plc | Pharmaceutical formulation |
-
1994
- 1994-03-24 GB GB9405856A patent/GB9405856D0/en active Pending
-
1995
- 1995-03-20 WO PCT/EP1995/001039 patent/WO1995025516A1/en not_active Application Discontinuation
- 1995-03-20 EP EP95928859A patent/EP0751771A1/en not_active Withdrawn
- 1995-03-20 JP JP7524382A patent/JPH09510470A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0751771A1 (en) | 1997-01-08 |
JPH09510470A (en) | 1997-10-21 |
WO1995025516A1 (en) | 1995-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB9407386D0 (en) | Pharmaceutical formulation | |
GB9402203D0 (en) | Pharmaceutical formulation | |
IL112521A0 (en) | Pharmaceutical formulation | |
ZA953236B (en) | Pharmaceutical formulations | |
GB9519363D0 (en) | Pharmaceutical formulation | |
ZA951781B (en) | Pharmaceutical formulations | |
EP0862431A4 (en) | Pharmaceutical formulation | |
GB9405856D0 (en) | Pharmaceutical formulation | |
GB9416599D0 (en) | Pharmaceutical formulation | |
GB9523566D0 (en) | Pharmaceutical formulation | |
GB9408053D0 (en) | Pharmaceutical preparation | |
ZA96526B (en) | Novel pharmaceutical formulation | |
GB9709739D0 (en) | Pharmaceutical formulation | |
GB9418550D0 (en) | Drug formulation | |
GB9413542D0 (en) | Pharmaceutical formulations | |
GB9425074D0 (en) | Pharmaceutical formulation | |
GB9425075D0 (en) | Pharmaceutical formulation | |
GB9412395D0 (en) | Pharmaceutical formulation | |
ZA952013B (en) | Pharmaceutical preparation | |
GB9603141D0 (en) | Pharmaceutical formulation | |
GB9426113D0 (en) | Pharmaceutical formulations | |
GB9408162D0 (en) | Pharmaceutical formulations | |
GB9408151D0 (en) | Pharmaceutical formulations | |
GB9401738D0 (en) | Pharmaceutical formulations | |
GB9408163D0 (en) | Pharmaceutical formulations |